Oncotarget

Research Perspectives:

Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia

PDF  |  Full Text  |  How to cite

Metrics: PDF 2045 views  |  Full Text 3319 views

Jan Philipp Bewersdorf1 and Amer M. Zeidan1,2

1 Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA

2 Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA

Correspondence to:

Amer M. Zeidan,email: amer.zeidan@yale.edu

Keywords: acute myeloid leukemia; AML; PLK-1 inhibitor; onvansertib; volasertib

Received: February 24, 2021     Accepted: March 08, 2021     Published: June 22, 2021

Copyright: © 2021 Bewersdorf and Zeidan. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.